Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a serious, complex, multi-system disease. It is not a psychological condition, not laziness, and not 'just tiredness'. It is recognised by the World Health Organization and classified as a neurological condition (ICD-10: G93.3). For those living with it, and for the clinicians who support them, an honest, up-to-date understanding is essential.
ME/CFS is characterised by profound fatigue lasting six months or more, post-exertional malaise (PEM) — a worsening of symptoms following even modest physical or cognitive effort — cognitive impairment ('brain fog'), unrefreshing sleep, and often orthostatic intolerance (symptoms worsening on standing). The hallmark feature, PEM, distinguishes ME/CFS from ordinary fatigue and is critical for diagnosis and management.
Estimates suggest ME/CFS affects between 0.2% and 0.4% of the population globally — millions of people. Many remain undiagnosed for years. Post-COVID illness has significantly increased awareness of ME/CFS-like presentations, as many people with long COVID meet diagnostic criteria for ME/CFS.
There is no diagnostic biomarker for ME/CFS — diagnosis is clinical, based on symptom criteria. The 2015 National Academy of Medicine (NAM) diagnostic criteria require the presence of substantially impaired activity, PEM, unrefreshing sleep, and either cognitive impairment or orthostatic intolerance. A thorough medical workup is needed to exclude other conditions.
Management of ME/CFS has evolved significantly. Approaches that were previously recommended — including Graded Exercise Therapy (GET) and Cognitive Behavioural Therapy focused on 'deconditioning' beliefs — have been substantially revised based on patient experience and updated evidence. The current understanding is that these approaches carry risk of harm in patients with true PEM.
Current evidence-supported approaches include:
• Pacing: The single most important self-management strategy. Pacing involves identifying one's current energy envelope and carefully staying within it, avoiding the boom-and-bust cycle that triggers PEM. Heart rate monitoring can help patients gauge their limits objectively.
• Symptom management: Individual symptoms — pain, sleep disturbance, orthostatic intolerance, cognitive symptoms — are addressed specifically and pharmacologically where effective options exist.
• Specialist multidisciplinary care: ME/CFS specialist clinics, where available, can provide coordinated assessment, management planning, and support for both patients and their families.
Widespread musculoskeletal pain — myalgia and arthralgia — is among the most common and debilitating symptoms of ME/CFS, reported by the majority of patients. This pain is real, often severe, and frequently under-treated. It significantly impairs quality of life beyond the fatigue itself.
Pain management in ME/CFS is challenging because many patients are sensitive to medications and because exertion — including some physical therapies — can worsen symptoms. Non-pharmacological, low-effort pain management approaches are therefore of particular interest.
Microcurrent electrotherapy involves placing electrode pads on painful areas of the body and delivering gentle electrical stimulation. The KFH Energy is FDA-cleared for pain relief (510(k) K073008). Because its use is passive — the patient can rest during treatment — it is compatible with pacing principles. Some ME/CFS patients use pain relief devices as part of their overall symptom management toolkit.
To be explicit: KFH Energy is a pain relief device. ME/CFS is not an approved indication. KFH Energy does not address the underlying mechanisms of ME/CFS, does not treat fatigue, and does not prevent or reduce PEM. It may provide some patients with relief from the pain symptoms that accompany their condition. Its use should always be discussed with the treating clinician.
Living well with ME/CFS requires a significant recalibration of expectations and approaches. It often means accepting a reduced activity level, building careful routines, and prioritising rest and recovery. Support groups and patient communities — national ME/CFS associations exist in most countries — provide invaluable practical knowledge and emotional support.
Research into ME/CFS is intensifying, driven partly by the long COVID experience. New diagnostic biomarkers and potential therapeutic targets are being actively investigated. There is genuine reason for cautious optimism.
DISCLAIMER: ME/CFS is a complex medical condition requiring specialist assessment and management. This article is for informational purposes only and does not constitute medical advice. KFH Energy is an FDA-cleared pain relief device (510(k) K073008) and is not indicated for the treatment of ME/CFS or fatigue. Please consult your GP and, where possible, an ME/CFS specialist. Individual results may vary.
